by\u00a0Jim H\u1d0fft\u00a0<\/p>\n\n\n\n
Major Big Pharma companies have abruptly halted their latest COVID-19 mRNA \u201cbooster\u201d trial because they literally couldn\u2019t find enough willing participants.<\/p>\n\n\n\n
After years of gaslighting the American public, raking in hundreds of billions in profits from experimental shots that were shoved down our throats under the guise of \u201cpublic health,\u201d the same corporations that partnered with the Biden regime, Anthony Fauci, and the lying mainstream media are now facing the cold, hard reality: Americans are done being lab rats.<\/p>\n\n\n\n
According to internal letters sent to trial investigators and obtained by Reuters<\/a>, Pfizer is ending its study of \u201cupdated\u201d shots in healthy adults aged 50 to 64.<\/p>\n\n\n\n The company admitted it was \u201cunable to generate relevant data\u201d because recruitment had effectively hit a brick wall.<\/p>\n\n\n\n Reports indicate that more than 80% of potential recruits didn\u2019t even make it past pre-screening, or simply refused to participate.<\/p>\n\n\n\n The trial, which aimed to enroll a massive 25,000 to 30,000 participants, folded after failing to meet even the most basic enrollment targets.<\/p>\n\n\n\n This comes at a time when the \u201cscience\u201d is being scrutinized like never before. Under the current administration, the FDA has been pressured to actually require randomized placebo-controlled trials, <\/em>the very thing skeptics have been demanding for years.<\/p>\n\n\n\n It seems that when Big Pharma actually has to play by the rules and prove efficacy to a skeptical public, they simply can\u2019t find the \u201cvolunteers\u201d anymore.<\/p>\n\n\n\n Pfizer isn\u2019t the only one feeling the heat. Moderna is reportedly facing similar \u201crecruitment challenges\u201d for its own 30,000-person study.<\/p>\n\n\n\n BioSpace reported:<\/a><\/p>\n\n\n\n Pfizer and BioNTech told Reuters<\/em> they are halting the study because slow enrollment is preventing them from generating relevant post-marketing data on the vaccine. \u201cThis is a very difficult population to recruit,\u201d an unnamed executive at a contract research organization involved in the trial added on the condition of anonymity. People with chronic conditions such as hypertension or diabetes were ineligible for the study.<\/p>\n\n\n\n \u201cEven when patients are willing to participate in COVID studies, more than 80% fail at prescreening because they don\u2019t meet the health criteria,\u201d the executive told Reuters<\/em>. \u201cIt\u2019s been a real challenge to enroll enough patients, particularly given the scale of these trials.\u201d<\/p>\n\n\n\n The news comes after the FDA imposed new requirements on COVID-19 vaccines last year. In May, the agency announced<\/a> it would require data from placebo-controlled trials<\/a> to inform decisions about whether to support the use of COVID-19 vaccines in people aged 50 to 64. Neither Pfizer and BioNTech\u2019s Comirnaty nor Moderna\u2019s Spikevax and next generation mNEXSPIKE has full approval in this age group.<\/p>\n\n\n\n Moderna is also running a COVID-19 vaccine trial in people aged 50 to 64. Sources at four sites involved in the study told Reuters<\/em> that the company is also facing enrollment challenges. Moderna has yet to comment on the trial\u2019s enrollment rate, although commercial challenges in the U.S. vaccine market could suggest a dip in the number of people interested in the trial.<\/p>\n<\/blockquote>\n","protected":false},"excerpt":{"rendered":" by\u00a0Jim H\u1d0fft\u00a0 Major Big Pharma companies have abruptly halted their latest COVID-19 mRNA \u201cbooster\u201d trial because they literally couldn\u2019t find enough willing participants. After years of gaslighting the American public, […]<\/p>\n","protected":false},"author":2,"featured_media":14641,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[669,89,607],"tags":[],"class_list":["post-14628","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-adenovirus-vector-vaccines","category-clinical-trials","category-vaccine-news"],"_links":{"self":[{"href":"https:\/\/cov19longhaulfoundation.org\/index.php?rest_route=\/wp\/v2\/posts\/14628","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/cov19longhaulfoundation.org\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/cov19longhaulfoundation.org\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/cov19longhaulfoundation.org\/index.php?rest_route=\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/cov19longhaulfoundation.org\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=14628"}],"version-history":[{"count":1,"href":"https:\/\/cov19longhaulfoundation.org\/index.php?rest_route=\/wp\/v2\/posts\/14628\/revisions"}],"predecessor-version":[{"id":14629,"href":"https:\/\/cov19longhaulfoundation.org\/index.php?rest_route=\/wp\/v2\/posts\/14628\/revisions\/14629"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/cov19longhaulfoundation.org\/index.php?rest_route=\/wp\/v2\/media\/14641"}],"wp:attachment":[{"href":"https:\/\/cov19longhaulfoundation.org\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=14628"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/cov19longhaulfoundation.org\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=14628"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/cov19longhaulfoundation.org\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=14628"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}\n